The FDA has granted 510(k) marketing clearance to the first in vitro blood-based biomarker diagnostic device for Alzheimer’s ...

The test is for those aged 55 and older who are already exhibiting signs and symptoms of the disease, the FDA says.

The US Food and Drug Administration has given marketing clearance to a blood test to help diagnose Alzheimer’s disease, ...

The test can aid doctors in determining whether a patient's memory problems are due to Alzheimer's or a number of other ...

The US Food and Drug Administration (FDA) has awarded 510(k) clearance to Fujirebio’s Lumipulse G pTau 217/β-Amyloid 1-42 ...

The Food and Drug Administration has approved the first blood test for diagnosing Alzheimer's disease, the agency announced ...

U.S. regulators have approved the first blood test to help diagnose Alzheimer’s disease, potentially making it easier to find ...

Japan-based Fujirebio's test, which helps doctors diagnose Alzheimer's disease, is intended for patients with signs of ...

The US on Friday approved the first blood test for Alzheimer's, a move that can help patients begin treatment earlier with ...

The United States on Friday approved the first blood test for Alzheimer's, a move that could help patients begin treatment ...

Credit: Krakenimages.com / Shutterstock. The Global Health Innovative Technology (GHIT) Fund has awarded a $4.5m grant to US-based diagnostic developer Fluxus, a Fujirebio subsidiary, to develop an ...

To address this issue, the GHIT Fund has decided to invest approximately JPY 679 million (USD 4.5 million 1) towards a new TB diagnostic development project by US-based diagnostic developer Fluxus, ...